“…Indeed, Suga et al developed an mRNA display-based selection method, referred to as the Random nonstandard Peptides Integrated Discovery system, which enables the selection of peptides containing nPAAs using a reprogrammed genetic code with flexizyme-charged nPAA-tRNAs. Such systems provide a good drug-discovery platform for the development of structurally unique peptide ligands containing nPAAs [44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61].…”